Your browser is old and unsupported. Please upgrade!
Raise Funding
Sign Up   Login
SUMMARY

Immusoft Corporation

Programming a patient's cells to become miniature drug factories.

video

Immusoft’s platform, Immune System Programming (ISP™) is a new medical paradigm, which can program cells to continually produce and secrete therapeutic proteins and rare antibodies that have been impossible to elicit with a vaccine. ISP™ offers many benefits of traditional approaches and modern gene therapy with less risk and greater control; replacing lifelong infusions with drug-producing cells

  • Program a patient's cells to produce antibodies, and enzymes
  • Scope of applicability extensive; for use in many diseases
  • Enables an entire new set of treatments options for patients
  • Patient convenience; eliminates frequent needle injections

Product

The Cost of Health Care Failure
November 18, 2013
“The future of pharma is to learn to address the human body as an information platform. A company in Seattle named Immusoft, partly financed by venture investor Peter Thiel, has been successfully pursuing this strategy and proven its feasibility [for HIV and other diseases] in mice, using viruses and other vectors to program immune cells to emit needed molecules.” -- George Gilder, columnist and futurist
Mini drug factory churns out drugs from inside bone
September 18, 2013
"If they can achieve therapeutic levels of antibody, this could be a real advance in cellular therapy" - Dr. David Baltimore, Nobel Laureate for Immunology, Professor at Caltech "It's a very attractive idea to supply stable levels of antibodies from a cellular source in the body. The challenge is finding the right cell that would persist for the desired amount of time – days, or years in some cases – and that's a big challenge." - Dr. Michael Sadelain, Memorial Sloan-Kettering Cancer Center "It might be possible to recreate the biochemical environment of youth." - Matt Scholz, CEO Immusoft
Immusoft Applies Computer Science Knowledge to Disease
November 15, 2012
"Instead of letting the body try to randomly patch up the right combination to grab onto whatever it's attacking, we could leverage computational power to develop that novel protein or antibody in a computer and then simply tell the body how to make it." - Matt Scholz, CEO
A Computer Guy's Dream, Immusoft, Turns Cells Into Drug Factories
July 5, 2012
It has no venture capital backing and just four employees, but in April, the company was one of six startups to win a grant from the Thiel Foundation, which aims to support what it calls “radical scientific innovations.” - Luke Timmerman - National Biotech Editor of Xconomy
Peter Thiel's Breakout Labs Awards $350K Each To Six Ambitious Biotech Startups
April 17, 2012
"We want to take advantage of the revolution in healthcare and science that is happening and reward companies who are operating in a nimble way," circumventing the slow moving institutions of academia and traditional grants." - Lindy Fishburne, Executive Director Breakout Labs a project of the Thiel Foundation
Immusoft Awarded NIH Grant
April 15, 2012
“The goal of this study is to use Immusoft’s ISP™ platform to make human cells produce VRC01, an antibody that neutralizes many strains of HIV, in a mouse. Once we can demonstrate that the mouse cells can produce VRC01, we'll move on to primates, and then human trials.” - Dr. Eric Herbig, CSO
Large_imgres Large_press_scientist Large_bioworld Large_10611194-xconomy-logo Large_logo_breakoutlabs Large_niaid_logo

Meet the Founders

Opening a new frontier in biomedicine

Immusoft’s mission is to develop a breakthrough platform for delivering targeted medicines — programming a patient’s own cells to become miniature drug factories.

Founder and CEO Matthew Scholz conceived the concept in 2008. A computer scientist by training, Scholz reasoned that since the human body is fundamentally a complex information-based system written in DNA, it should be possible to program the body like we program computers.

To explore that possibility, Scholz spent over 18 months before founding Immusoft consulting dozens of the world’s top scientists in molecular biology, immunology, and genetic engineering, many of whom he was able to later recruit as advisors. His quest also led him to the lab of Nobel Laureate David Baltimore at Caltech, where he uncovered an innovation that became the basis for Immusoft’s core technology.

Founded in 2009, Immusoft has already had achieved some significant success. All major research milestones have been met, which has validated that the core technology works and is viable. In addition to our distinguished list of academic and scientific advisors, we have recruited top advisors in biotech commercialization. We have received grants from the National Institutes of Health and Peter Thiel's Breakout Labs as well as support from private investors, including the former head of preclinical development at Seattle Genetics. Finally, we have an exclusive license option on our core technology from Caltech and have filed two additional patents covering our extensive modifications to the technology.

Today Immusoft is seeking funding to perform additional preclinical animal studies in preparation of our clinical trials.

Our technology turns cells into miniature drug factories
It’s no secret that DNA instructs cells to make antibodies, enzymes, peptides and every protein in the body. Immusoft has developed a commercially viable way to use DNA as “source code” to instruct the human body to produce a desired therapeutic protein (biologic) to fight a specific disease.

Once optimized, the process will be revolutionarily simple: The patient will go to the clinic for a simple blood draw, and then the patient’s own cells will be “programmed” by Immusoft’s proprietary technology to start producing the specific biologic needed to treat his or her disease. The programmed cells will be injected back into the patient, where they will start their ongoing mission of delivering a consistent and sustained dose of the biologic. One treatment could last for years.

So, what does that mean for the patient? Today there are scores of rare and orphaned diseases that inflict such a small portion of the population, it’s not commercially viable to find a treatment. Or, in some cases, there is a biologic available that could treat the disease, but it requires the patient to undergo a lifetime of regular, sometimes daily, injections. Immsoft’s platform technology will eliminate these hurdles, opening new frontiers in biomedicine.

Early stage results have been promising
We’ve successfully completed our proof of concept and every milestone to date. Specifically, we’ve taken human cells from a simple blood draw and reprogrammed them to produce very rare, potent antibodies against HIV, as well as missing enzymes from people with rare genetic diseases. We’ve tested our technology in mice and the cells have demonstrated long-term survival, which was a critical finding.

We are two years away from human trials
We’re working with prominent experimental HIV medicine scientists at the University of California, San Francisco to conduct our first human trials and collaborating with leading biopharmaceutical companies to advance our rare disease treatments. Our next steps will be to scale up to clinical-grade production with our collaborators at the Fred Hutchinson Cancer Research Center, and get approval from the FDA to begin our human clinical trials as early as 2016.
Large_eric_herbig
Dr. Eric Herbig
Chief Science Officer
Large_matthew_scholz
Matthew Scholz
Chief Executive Officer

--- and the rest of the team ---

Square_jane_yoo
Dr. Jane Yoo
Director of Cell Analysis
Square_charlie_liu
Charlie Lui M.Sc
Research Scientist
Square_mei_pic_144x180__1_
Dr. Mei Xu
Director of Research

We've raised $0
from 6 investors

Round 1
$0
In Progress

Interview

How will you make money?

    At this point, Immusoft anticipates several key revenue streams.

    The ISP™ platform will be out-licensed to biopharmaceutical companies seeking a robust, FDA-approved drug delivery technology to deliver life-saving biologic-based medicines to patients. We have already started discussions with biopharmaceutical companies interested in using the technology for the delivery of broadly neutralizing antibodies to HIV as well as those who are interested in using ISP™ for enzyme replacement therapy.

    After ISP™ has been FDA-approved for a single indication (i.e. HIV or MPS I), biopharmaceutical companies will have greater incentive to use it in place of batch-to-batch scale-up of current Good Manufacturing Practice (cGMP) produced biologic medications — a precise and costly method to produce these types of medications. ISP™ largely eliminates the need for industrial-sized commercial bioreactors to produce protein therapeutic drugs. A partnership with a biopharmaceutical company to take our first indication into human clinical trials to receive FDA approval will provide this benchmark.

    Separate from licensing ISP™ to biopharmaceutical companies to use, the treatment of rare genetic disorders also offers a unique business opportunity for Immusoft.

    With fewer than 5,000 patients worldwide, MPS I, for example, has a small patient population. Immusoft would offer to treat MPS I patients directly using cGMP disposable bioreactor technology commercially available from GE Healthcare (i.e. Wave Bioreactor™) or an advanced closed system bioreactor created specifically for cellular therapy from Miltenyi Biotec (i.e. CliniMACS Prodigy™).

    Currently, patients suffering from lysosomal storage disorders are charged between $250,000 and $400,000 yearly for their medication, and endure multiple-hour drug infusions every week. The annual market for MPS I is $180M. There are seven different types of MPS lysosomal storage disorders and several other lysosomal storage disorders with FDA-approved medications for which Immusoft’s ISP™ technology could be effective, including Gaucher’s disease, Fabry’s disease, and Pompe disease. Treatment of rare genetic diseases with ISP™ technology would likely require several doses of ISP™ cell therapy product. However, once enough cells have engrafted and blood serum levels of the medication are present, the patient would not require infusions of the drug intravenously.

    ISP™-modified cells can be frozen and banked for administration at some point in the future if necessary. In this capacity, our ISP™ cell therapy product represents a disruptive technology to companies like BioMarin and Genzyme, which receive huge profits from the manufacture and distribution of these medications for intravenous infusions worldwide. The convenience of ISP™ technology as well as the sustained production of the medication by the patient’s own cells is thought to provide significant benefit over intravenous drug infusions. Moreover, Immusoft can treat patient populations of fewer than 100 patients, something that would be economically infeasible for biopharmaceutical companies to scale using the conventional bioreactor approach.

    Several private foundations exist for these neglected lysosomal storage diseases. ISP™ technology offers the hope that some of these could be treatable with an approach like ours.

    The combination of royalties from licensing relationships with biopharmaceutical companies and revenues from direct sales of ISP™ cell therapy products will account for a significant portion of our revenues. So too, we anticipate, would be FDA-approval of ISP™ technology indications with larger patient populations and consequently larger market sizes, such as heart disease, which is worth more than $100M annually.

    All three of those revenue streams combined put us within reach of privately funding the company through phase III clinical trials. We suspect that would make Immusoft an attractive acquisition for a large pharmaceutical company such as Pfizer or Merck.

    If Immusoft ever decided to provide an initial public offering it would likely come after FDA-approval of our first or second ISP™ cell therapy product.

How big is the market?

    Immusoft effectively is a part of four distinct markets: HIV treatments, treatments for rare genetic disorders (MPS I, Pompe, PKU, Hemophilia), heart disease, and out-licensing relationships.

    HIV, which is the fastest path to clinical trials, has a U.S. market value of more than $9B. The NIH paid for our HIV proof of concept, and our ISP™ cell therapy product can be used to produce two broadly neutralizing antibodies to HIV.

    The market for rare genetic disorders (MPS I, Pompe, PKU, Hemophilia) for which we could use ISP™ to treat by directing a cell therapy product to produce missing enzymes is $180M annually. Each of those four disorders — MPS I, Pompe, PKU, Hemophilia — has a market value of $6B. And with each of these, it is anticipated that the regulatory approval process would be faster and less expensive than either HIV or other indications such as heart disease.

    Heart disease has a market value of more than $100B. There is a well-documented, naturally occurring HDL protein that has proven effective in human trials. We would use a ISP™ cell therapy product to produce a better version of this naturally occurring HDL to remove arterial plaque.

    Finally, our out-licensing deals can be expected to be worth an estimated $10M to $250M, our direct sales of ISP™ cell therapy products worth an estimated $100M to more than $500M, and acquisition of the company by a leading biopharmaceutical company worth more than $1B.

What do you understand about the business that others just don't get?

We understand that progress has been hindered in the advancement of delivering biologic-based medicines because routine and frequent needle injections can incur more cost to the end user(s). Many of these life-saving medications cannot be delivered orally in a pill, and can cost between $250-$1000 per month — a prohibitive cost to most patients.

Enhanced delivery of protein therapeutic medicines like ISP™ enables drug discovery companies to do what they do best, design more effective molecular compounds for the treatment of disease. Immusoft has developed a platform technology that can deliver these drugs by simply replacing the source code that produces this sequence.

ISP™ technology enables the production of antibodies, which would be impossible to elicit with a vaccine using the conventional vaccine approach, can produce structurally engineered proteins which bind with higher affinity, and can replace a lifetime of infusions with a patient’s drug-producing cells.

Ten years ago a platform technology would have never made it to market simply because it would be too disruptive. Either the FDA would have never allowed it because it was too radical or biopharmaceutical companies would have lobbied against it because it would significantly interfere with profit margins.

What a difference a decade makes. The gene/cell therapy regulatory environment within the FDA (and abroad) is changing, and biopharmaceutical companies suffering from the extremely high cost of bringing a biologic to market (more than $1B on average) are seeking platform technologies that enable them to scale-up their medications to more users. Furthermore, crowd-investing platforms provide a mechanism where companies with disruptive technologies can thrive without the buy-in from venture capital investment funds that have typically acted as gatekeepers to innovative ideas.

The world of medicine and disease management changes daily. But even the best of medicines and treatments are nothing more than sugar water if they can’t be delivered effectively and efficiently. Immusoft’s ISP™ technology steps in to fill the void between therapeutic advances and the ability to deliver biologic-based medicines. We believe it’s the future of medicine. And we’re happy to shake up the system — to change the medical paradigm.

What are your biggest risks?

    We have mitigated many risks since founding the company in 2009. What follows are just a few of the challenges we’ve faced and solved:

    ·Can you insert DNA into an immune cell and secrete a desired protein? Yes.

    ·Will the secreted protein be produced in therapeutic quantities? Yes.

    ·Will the ISP™ cell therapy product engraft into the host? Yes.

    ·Can you eliminate the ISP™ cell therapy product from the host? Yes.

    ·Can you produce lysosomal storage enzymes? Yes.

    Risks we’re still working on solving:

    Scientific:

    ·Will the lysosomal storage enzymes be taken up into the enzyme-deficient cells?

    ·Will the sustained delivery of broadly neutralizing antibodies eradicate HIV permanently in a patient?

    Business:

    ·Will biopharmaceutical companies adopt the platform technology?

    ·Will we raise enough capital to enter a human clinical trial with a ISP™ cell therapy product to test the safety and efficacy of our treatment approach?

    ·Can the technology be scaled in order to be made available in hospitals and out-patient care facilities?

How do you acquire customers?

    We anticipate our customers will come through the following: partnership and distribution agreements with biopharmaceutical companies; private foundations (such as rare disease foundations like MPS I Society and Muscular Dystrophy Association); community outreach (HIV+ support groups); and, a comprehensive integrated marketing and communications as well as sales strategy.

    At this point, we’re primarily focused on the technology and clinical trials. If we can demonstrate the technology in a human clinical trial and receive FDA approval for an ISP™ cell therapy product, we will have cleared a major hurdle to successful commercialization of the ISP™ platform. Subsequent to that technical advance, we would focus increased efforts on more traditional customer development and relationship management functions.


Ask a Question

Signup

Already have an account? Login

Don't have an account? Signup

Privacy: We won’t share your data with Facebook without your explicit permission.
— or —